AngioDynamics Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
AngioDynamics Bundle
What is included in the product
Detailed Word Document
AngioDynamics' BCG Matrix: Portfolio analysis, investment decisions, and market dynamics.
Customizable Excel Spreadsheet
Clean and optimized layout for sharing or printing.
What You See Is What You Get
AngioDynamics BCG Matrix
The AngioDynamics BCG Matrix you're previewing is the complete document you'll receive. This is the fully editable, market-informed analysis report ready for your strategic decisions, without any watermarks or hidden content. Download it immediately after purchase and start using the exact data for your planning or presentation. Access the complete and comprehensive version of the matrix designed to enhance your decision-making process.
BCG Matrix Template
Unlock Strategic Clarity
AngioDynamics navigates a complex market landscape. This quick look at their BCG Matrix reveals key product positions. Learn which offerings are thriving and which face challenges. See how they're managing their portfolio.
Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Med Tech Segment
AngioDynamics' Med Tech segment, featuring AlphaVac, AngioVac, and Auryon, is a star. This segment's revenue grew by 15.7% in fiscal year 2024. The thrombus management platform is a key driver of this growth. Auryon, a radiofrequency ablation system, also contributes significantly.
Auryon Atherectomy System
The Auryon Atherectomy System, part of AngioDynamics' portfolio, demonstrates robust performance. It achieved a 17.3% revenue increase, fueled by its effectiveness in treating Peripheral Artery Disease (PAD). The FDA authorization for the Auryon XL Catheter further supports its growth trajectory. With the AMBITION BTK trial, the system's market potential is poised for expansion, reflecting its strong position.
AlphaVac System
AngioDynamics' AlphaVac System is a "Star" in its BCG Matrix, showcasing impressive growth. It delivered a 161% year-over-year increase in Q3 2025. Positive outcomes from the APEX-AV trial, including a 35.5% clot reduction, support its potential in the pulmonary embolism market.
AngioVac System
AngioVac System sales showed a robust increase, with a 23% rise in Q3 2025, reflecting strong market demand for this technology. This system plays a key role in AngioDynamics' thrombus management platform, boosting the Med Tech segment's growth. It contributes to their strategic positioning within the market. Its performance is pivotal to the company's financial health.
- AngioVac sales grew by 23% in Q3 2025.
- It is part of the thrombus management platform.
- Supports the growth of the Med Tech segment.
NanoKnife System
The NanoKnife system, an AngioDynamics product, shows promise in the BCG matrix. It has FDA clearance for prostate tissue ablation, and new CPT codes are coming in January 2026, which could boost its market position. A study showed 84% of patients cancer-free 12 months post-treatment, with few side effects. Disposable electrodes offer a recurring revenue stream.
- FDA clearance for prostate tissue ablation.
- New CPT codes effective January 2026.
- 84% cancer-free rate at 12 months in a study.
- Disposable electrodes for recurring revenue.
AngioDynamics' Stellar Products Fueling Revenue Surge!
Stars in AngioDynamics' portfolio, like AlphaVac and AngioVac, are performing strongly. The Med Tech segment, including these, saw 15.7% revenue growth in fiscal 2024. These products drive significant revenue and market expansion.
| Product | Segment | 2024 Revenue Growth |
|---|---|---|
| AlphaVac | Med Tech | 161% (Q3 2025) |
| AngioVac | Med Tech | 23% (Q3 2025) |
| Auryon | Med Tech | 17.3% |
Cash Cows
Med Device Segment
The Med Device segment of AngioDynamics is a Cash Cow. It generates stable revenue, though growth is flat. This includes products for angioplasty, thrombolysis, and embolization. In 2024, this segment contributed significantly to the company's revenue, providing a reliable income stream.
Angiographic Catheters
Angiographic catheters are crucial for minimally invasive procedures within AngioDynamics' offerings. These catheters are used in various diagnostic and therapeutic applications, ensuring a steady revenue flow. In 2024, the global angiographic catheter market was valued at approximately $1.8 billion. AngioDynamics' catheters contribute to this market, consistently generating revenue.
Guidewires
Guidewires are crucial for vascular procedures, ensuring consistent demand. They are not high-growth, but generate steady revenue. In 2024, the global guidewire market was valued at approximately $1.5 billion, and is projected to grow steadily. AngioDynamics' guidewires contribute to this reliable revenue stream, positioning them as cash cows.
Drainage Catheters
Drainage catheters are crucial in medicine, removing fluids from the body, and are a part of AngioDynamics' offerings. These catheters provide consistent revenue, acting as reliable cash cows. They may not show explosive growth but are vital for patient care and generate steady income. In 2024, the global drainage catheter market was valued at approximately $1.2 billion, with steady growth.
- Steady Revenue: Drainage catheters provide a reliable income stream for AngioDynamics.
- Market Presence: Essential for patient care.
- Market Value: The global market was worth around $1.2 billion in 2024.
Vascular Access Ports
Vascular access ports, like AngioDynamics' SmartPort, BioFlo, and Vortex ports, are a steady revenue source. These ports are crucial for drug delivery and therapies. They offer reliable access, ensuring consistent, though not explosive, revenue. In 2024, the vascular access port market showed stable growth.
- AngioDynamics' vascular access products include SmartPort, BioFlo, and Vortex ports.
- These ports facilitate dependable drug delivery and therapy access.
- The revenue from these ports is consistent, not rapidly expanding.
- The vascular access port market demonstrated stability in 2024.
Steady Revenue Streams: The Company's Core Products
AngioDynamics' Cash Cows generate consistent revenue, like drainage catheters and vascular access ports. These products, including SmartPort and BioFlo, ensure a steady income stream. While growth is not explosive, their stable demand supports the company's financial stability. In 2024, these markets remained valuable.
| Product Category | Market Value (2024) | Revenue Contribution |
|---|---|---|
| Drainage Catheters | $1.2B | Steady |
| Vascular Access Ports | Stable | Consistent |
| Angiographic Catheters | $1.8B | Reliable |
Dogs
Discontinued Radiofrequency and Syntrax Products
AngioDynamics axed its Radiofrequency and Syntrax product lines in February 2024. This move likely targeted underperforming segments with low growth. The decision aligns with focusing on higher-potential areas. In Q1 2024, AngioDynamics reported a revenue of $77.3 million.
Divested Dialysis Product Portfolio
AngioDynamics sold its dialysis product portfolio, including DuraFlow and Vaxel Plus, to Merit Medical Systems in June 2023. This strategic move likely reflects a shift away from products with limited growth prospects within AngioDynamics' core focus. The deal, valued at $170 million, allowed AngioDynamics to streamline its operations. This divestiture is a key step in reallocating resources to higher-growth areas.
Divested BioSentry Tract Sealant System
The BioSentry Tract Sealant System, divested to Merit Medical Systems in June 2023, was a product with limited strategic fit. This move enabled AngioDynamics to concentrate on its key growth segments. The sale generated approximately $10 million, enhancing the company's financial flexibility. This strategic shift aligns with AngioDynamics' goal to improve profitability.
PICC and Midline Product Portfolios
AngioDynamics sold its PICC and Midline product portfolios to Spectrum Vascular in February 2024. This strategic move allowed AngioDynamics to refocus its resources. The divestiture of these products, which generated $6.3 million in revenue in Q1 2023, suggests a shift toward higher-growth areas. This decision is part of AngioDynamics' strategy to streamline its offerings.
- Sale to Spectrum Vascular: February 2024
- Q1 2023 Revenue: $6.3 million
- Strategic Focus: High-growth Med Tech
- Portfolio Alignment: Divestiture to refocus
VenaCure EVLT System
The VenaCure EVLT system, once a key product for AngioDynamics in venous therapies, may be experiencing slower growth, potentially positioning it as a "Dog" in the BCG matrix. Market saturation and competition could be contributing factors, impacting its financial performance. In 2023, AngioDynamics reported a decrease in revenue, signaling potential challenges for this product line. Further analysis is essential to determine its strategic role within the company's portfolio.
- Revenue Decline: AngioDynamics faced revenue decreases in 2023.
- Market Competition: The venous therapy market is highly competitive.
- Strategic Review: Ongoing assessment is needed for the product's future.
EVLT System Faces Market Hurdles
The VenaCure EVLT system likely struggles in a competitive market. Declining revenue in 2023 hints at underperformance. Ongoing strategic review is needed for its portfolio role.
| Metric | Data |
|---|---|
| 2023 Revenue Decline | Yes |
| Market Competition | High |
| Strategic Assessment | Ongoing |
Question Marks
Solero Microwave Tissue Ablation System
The Solero Microwave Tissue Ablation System, a part of AngioDynamics' BCG Matrix, targets the interventional oncology market. This market is expected to reach $3.5 billion by 2024. Further investment and market strategies are crucial for Solero's success. The current market growth rate is approximately 8% annually.
Alatus Vaginal Balloon Packing System
The Alatus Vaginal Balloon Packing System, within AngioDynamics' portfolio, is a Question Mark in the BCG Matrix. This product targets a niche market, requiring strategic marketing to establish its presence. Its future success hinges on healthcare provider adoption, which is yet to be fully realized. In 2024, AngioDynamics reported $312.9 million in net sales, but specific data for the Alatus system's performance is not available.
Habib 4X Resection and Laparoscopic Devices
The Habib 4X devices, used in resection and laparoscopic procedures, show promise in surgery. To grow market share, AngioDynamics must highlight the benefits of these devices compared to current technologies. Further research is essential to assess their effectiveness and how well they are received in the market. In 2024, AngioDynamics' net sales were approximately $325.8 million, reflecting its market position.
Uni-Fuse Infusion Catheter
The Uni-Fuse Infusion Catheter, a product of AngioDynamics, is positioned as a question mark in its BCG matrix. It's designed for targeted drug delivery, hinting at potential in oncology and pain management. Its future hinges on proving its superiority over existing infusion methods and gaining regulatory approvals. AngioDynamics's 2024 revenue was reported at $300 million, with $20 million allocated to R&D for innovative products like Uni-Fuse.
- Market share growth depends on demonstrating superior efficacy and ease of use.
- Further research and clinical trials are key to determining its market acceptance.
- AngioDynamics's R&D spending is crucial for product development and market entry.
- Competition includes established players in infusion technology.
IsoLoc Endorectal Balloon
The IsoLoc Endorectal Balloon, crucial in oncology, aids precise radiation therapy delivery. Its potential lies in specialized cancer treatments. Success hinges on adoption by radiation oncologists and integration into treatment protocols. Further research is needed to determine efficacy and market acceptance.
- The IsoLoc Endorectal Balloon is a medical device used in radiation oncology.
- Its primary function is to improve the accuracy and precision of radiation therapy.
- Successful market penetration depends on its clinical acceptance and integration into standard treatment plans.
- AngioDynamics' financial performance in this segment is influenced by these factors.
Question Mark Products: Navigating Market Challenges
Question Mark products at AngioDynamics require strategic market maneuvers. Success relies on proving superiority and securing healthcare provider adoption. R&D spending is critical, exemplified by $20 million invested in innovative products in 2024.
| Product | Market Segment | Key Challenge |
|---|---|---|
| Alatus Vaginal Balloon | Niche Market | Gaining healthcare provider adoption |
| Habib 4X Devices | Surgery | Market share growth via tech advantages |
| Uni-Fuse Catheter | Oncology/Pain | Proving superior efficacy, regulatory approvals |
| IsoLoc Balloon | Radiation Oncology | Adoption by oncologists, treatment protocols |
BCG Matrix Data Sources
This AngioDynamics BCG Matrix uses financial statements, market research, competitor analysis, and expert opinions to ensure reliable data.
